// App-Quantinova.ai

e17076 : Identification of druggable targets in high-grade epithelial ovarian cancer (EOC) using next generation sequencing (NGS)based molecular diagnostic.

Researchers

Presenter

  • Jean-Louis Merlin

Principal Investigators

  • Shuhui Chen

  • Julia Salleron

  • Elisa Cavazza

  • Catherine Barlier

  • Celine Gavoille

  • Pierre Filhine-Tresarrieu

  • Alexandre Harle

Medical Centers

  • Institut de Cancerologie de Lorraine, Service de Biopathologie, CNRS UMR 7039 CRAN Universite de Lorraine, Nancy, France

  • Institut de Cancerologie de Lorraine, Nancy, France

  • Institut de Cancerologie de Lorraine, Service de Biopathologie, Nancy, France

  • Institut de Cancerologie de Lorraine, Departement d'Oncologie Medicale, Nancy, France

Locations

  • France

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Ovarian cancer

  • High-grade serous carcinoma

  • Gynaecological cancer

  • Solid malignancies

Biomarkers

  • B-Raf proto-oncogene, serine/threonine kinase

  • Breast cancer type 1 susceptibility protein

  • Phosphatase and tensin homolog

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • GTPase Nras

  • KRAS proto-oncogene, GTPase

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved